A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT06658626
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
MALE
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • [¹⁴C]Enlicitide chloride — DRUG
    IV Injection

Study Details

The purpose of this study is to learn what happens to enlicitide chloride labeled with \[¹⁴C\] in a person's body over time. A label can be added to a study medicine to trace it in a person's body.

Key Dates

Start date
Mar 10, 2023
Status verified
Oct 2024
Primary completion
Aug 2, 2023
Completion
Aug 2, 2023

Study Design

Enrollment
8 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: [¹⁴C]Enlicitide chloride
    Participants will receive a single dose of \[¹⁴C\]enlicitide chloride on Day 1.

Primary Outcome Measure

Cumulative Amount of Radioactivity Excreted in Urine (Aeu) [ Time Frame: At designated timepoints (up to 15 days) ]

Locations (1)

FacilityCityStateZIPSite coordinators
Labcorp Clinical Research Unit Inc. (Site 0001)MadisonWisconsin53704-

Find similar trials in Madison, WI

By research site
Labcorp Clinical Research Unit Inc.· Madison, WI

Related Studies